Institutional Biosafety Committee
The MaineHealth Institutional Biosafety Committee (IBC) is a standing committee that has oversight of recombinant DNA (rDNA) research. All NIH funded rDNA research must be reviewed by the IBC per NIH Guidelines for Research Involving Recombinant DNA Molecules.
All activities proposed to involve the use of recombinant DNA must first seek approval from the Institutional Biosafety Committee. The IBC reviews and approves research to ensure safe practices, procedures, as well as handling and use of biohazardous materials for research at MaineHealth Institute for Research.
IBC meetings are held as needed. The most likely date of an IBC meeting is directly before or after a scheduled Institutional Animal Care and Use Committee (IACUC) meeting (see IACUC 2025 meeting schedule).
Questions? Contact: Calvin Vary, PhD, IBC Chairman
